AMENDMENTS TO THE SPECIFICATION

Please delete the Sequence Listing in the International Application and replace it with the Sequence Listing attached hereto.

In the specification at page 1, after the title and before line 3, please insert the following new paragraph:

RELATED APPLICATIONS

This application is a national stage application (under 35 U.S.C. § 371) of PCT/EP2005/050874 filed March 1, 2005, which claims benefit of European application 04100814.5 filed March 1, 2004 and United States provisional application 60/550,918 filed March 5, 2004.

In the specification at page 22 line 17, please replace the paragraph starting with "The *Arabidopsis* CDKD1;1" with the following amended paragraph:

The *Arabidopsis* CDKD1;1 was amplified by PCR using as template an *Arabidopsis thaliana* seedling cDNA library (Invitrogen, Paisley, UK). After reverse transcription of RNA extracted from seedlings, the cDNAs were cloned into pCMV Sport 6.0. Average insert size of the bank was 1.5 kb, and original number of clones was of $1.59x10^7$ cfu. Original titer was determined to be $9.6x10^5$ cfu/ml, after first amplification of $6x10^{11}$ cfu/ml. After plasmid extraction, 200 ng of template was used in a 50 µl PCR mix. Primers prm2676 (sense, start codon in bold, AttB1 site in italic: 5' *GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACA* – **ATG**GAACAGCCGAAGAAAG 3'; SEQ ID NO: 4) and ~~prm3677~~ prm2677 (reverse, complementary, stop codon in bold, AttB2 site in italic: 5' *GGGGACCACTTTGTACAAGAAAGCTGGGT* – CCTATAGGAACTCGAGA**TCA**AGTT 3'; SEQ ID NO: 5), which include the AttB sites for Gateway recombination, were used for PCR amplification. PCR was performed using Hifi Taq DNA polymerase in standard conditions. A PCR fragment of 1256 bp was amplified and purified also using standard methods. The first step

of the Gateway procedure, the BP reaction, was then performed, during which the PCR fragment recombines *in vivo* with the pDONR201 plasmid to produce, according to the Gateway terminology, an "entry clone", p2777. Plasmid pDONR201 was purchased from Invitrogen, as part of the Gateway® technology.